TABLE OF CONTENTS
1 INTRODUCTION 30
1.1 OBJECTIVES OF THE STUDY 30
1.2 MARKET DEFINITION 30
1.3 OVERVIEW OF THE ASIA-PACIFIC COLORECTAL CANCER DIAGNOSTICS MARKET 30
1.4 LIMITATIONS 32
1.5 MARKETS COVERED 32
2 MARKET SEGMENTATION 35
2.1 MARKETS COVERED 35
2.2 GEOGRAPHICAL SCOPE 36
2.3 YEARS CONSIDERED FOR THE STUDY 36
2.4 CURRENCY AND PRICING 36
2.5 DBMR TRIPOD DATA VALIDATION MODEL 37
2.6 MULTIVARIATE MODELLING 40
2.7 PRODUCT TYPE LIFELINE CURVE 40
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 41
2.9 DBMR MARKET POSITION GRID 42
2.10 MARKET END-USER COVERAGE GRID 43
2.11 VENDOR SHARE ANALYSIS 44
2.12 SECONDARY SOURCES 45
2.13 ASSUMPTIONS 45
3 EXECUTIVE SUMMARY 46
4 PREMIUM INSIGHTS 49
4.1 PESTEL'S MODEL 50
4.2 PORTER'S 5 FORCES 51
4.3 LIST OF DISTRIBUTORS 52
5 HEALTHCARE ECONOMY 53
5.1 HEALTHCARE EXPENDITURE 53
5.2 CAPITAL EXPENDITURE 53
5.3 CAPEX TRENDS 54
5.4 CAPEX ALLOCATIONS 54
5.5 FUNDING SOURCES 55
5.6 INDUSTRY BENCHMARKS 56
5.7 GDP RATIO IN OVERALL GDP 56
5.8 HEALTHCARE SYSTEM STRUCTURE 57
5.9 GOVERNMENT POLICIES 58
5.10 ECONOMIC DEVELOPMENT 59
6 INDUSTRY INSIGHTS 60
6.1 MACRO AND MICRO ECONOMIC FACTORS 60
6.2 PENETRATION AND GROWTH PROSPECT MAPPING 62
6.3 KEY PRICING STRATEGIES 62
7 REIMBURSEMENT SCENARIO 64
8 STRATEGIC ANALYSIS 65
8.1 JOINT VENTURES 65
8.2 MERGERS AND ACQUISITIONS 65
8.3 LICENSING AND PARTNERSHIP 65
8.4 TECHNOLOGY COLLABORATIONS 66
9 TECHNOLOGY ROADMAP 67
10 VALUE CHAIN ANALYSIS 68
11 REGULATORY COMPLIANCE 70
11.1 REGULATORY AUTHORITIES 70
11.2 REGULATORY CLASSIFICATIONS 71
11.3 REGULATORY SUBMISSIONS 71
11.4 INTERNATIONAL HARMONIZATION 72
11.5 COMPLIANCE AND QUALITY MANAGEMENT SCENARIO 72
11.6 REGULATORY CHALLENGES AND STRATEGY 73
11.6.1 REGULATORY SCENARIO IN AUSTRALIA 73
11.6.2 REGULATORY SCENARIO IN JAPAN 73
11.6.3 REGULATORY SCENARIO IN CHINA 73
11.6.4 REGULATORY SCENARIO IN INDIA 74
12 MARKET OVERVIEW 75
12.1 DRIVERS 77
12.1.1 GROWING PREVALENCE OF COLORECTAL CANCER 77
12.1.2 RISE IN THE NUMBER OF PATIENTS SUFFERING FROM DIVERTICULITIS AND ULCERATIVE COLITIS 77
12.1.3 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS 78
12.2 RESTRAINTS 79
12.2.1 STRINGENT REGULATORY POLICIES 79
12.2.2 HIGH COST FOR COLORECTAL CANCER DIAGNOSIS 80
12.3 OPPORTUNITIES 80
12.3.1 INCREASED DEMAND FOR NON-INVASIVE TESTING METHODS 80
12.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS 81
12.4 CHALLENGES 82
12.4.1 LATE COLORECTAL CANCER DIAGNOSIS AND POOR PROGNOSIS 82
12.4.2 HIGH FALSE POSITIVES AND POOR SENSITIVITY OF CANCER DIAGNOSIS 83
13 ASIA-PACIFIC COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE 84
13.1 OVERVIEW 85
13.2 STOOL EXAMINATION 88
13.2.1 FECAL OCCULT BLOOD TEST (FOBT) 89
13.2.1.1 GUAIAC FECAL OCCULT BLOOD TEST (FOBT) 89
13.2.1.2 IMMUNOCHEMICAL FECAL OCCULT BLOOD TEST (FOBT) 89
13.2.2 FECAL IMMUNOCHEMICAL TEST (FIT) 89
13.2.3 STOOL DNA TESTING 89
13.3 BLOOD TEST 89
13.3.1 COMPLETE BLOOD COUNT (CBC) 90
13.3.2 TUMOR MARKER TEST 90
13.3.2.1 CARCINOEMBRYONIC ANTIGEN (CEA) 91
13.3.2.2 CA19-9 BIOMARKER TEST 91
13.3.2.3 HER2 PROTEIN 91
13.3.2.4 MSI AND MMR TESTING 91
13.3.2.5 CA 50 MARKER TEST 91
13.3.2.6 KRAS, NRAS, AND BRAF GENES 91
13.3.2.7 OTHERS 92
13.3.3 LIVER ENZYME BLOOD TEST 92
13.4 IMAGING TEST 92
13.4.1 COMPUTED TOMOGRAPHY (CT) SCAN 93
13.4.2 MRI 93
13.4.3 ULTRA SOUND 93
13.4.3.1 ABDOMINAL ULTRASOUND 94
13.4.3.2 ENDORECTAL ULTRASOUND 94
13.4.3.3 INTRAOPERATIVE ULTRASOUND 94
13.4.4 POSITION EMISSION TOMOGRAPHY (PET) 94
13.4.5 ANGIOGRAPHY 94
13.4.6 COLONOSCOPY 94
13.4.7 SIGMOIDOSCOPY 94
13.4.8 OTHERS 94
13.5 BIOPSY 94
13.5.1 ENDOSCOPIC BIOPSY 95
13.5.2 NEEDLE BIOPSY 95
13.5.2.1 FINE-NEEDLE ASPIRATION 96
13.5.2.2 CORE NEEDLE BIOPSY 96
13.5.3 OTHERS 96
13.6 OTHERS 96
14 ASIA-PACIFIC COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE 97
14.1 OVERVIEW 98
14.2 INSTRUMENTS 101
14.2.1 PATHOLOGY-BASED INSTRUMENTS 102
14.2.1.1 PCR INSTRUMENTS 102
14.2.1.2 SLIDE STAINING SYSTEMS 102
14.2.1.3 TISSUE PROCESSING SYSTEMS 102
14.2.1.4 CELL PROCESSORS 102
14.2.1.5 OTHER PATHOLOGY-BASED INSTRUMENTS 102
14.2.2 IMAGING INSTRUMENTS AND ACCESSORIES 103
14.2.2.1 INSTRUMENTS 103
14.2.2.1.1 ULTRASOUND SYSTEMS 104
14.2.2.1.2 CT SYSTEMS 104
14.2.2.1.3 MRI SYSTEMS 104
14.2.2.1.4 OTHERS 104
14.2.2.2 ACCESSORIES 104
14.2.2.2.1 CONTRAST AGENTS 105
14.2.2.2.1.1 BOWEL PREPARATION KITS 105
14.2.2.2.1.2 CONTRAST AGENTS 105
14.2.2.2.2 ENDORECTAL COILS AND PROBES 105
14.2.2.2.3 RADIOTRACERS 105
14.2.2.2.4 BOWEL PREPARATION KITS 105
14.2.3 BIOPSY INSTRUMENTS 106
14.2.4 OTHERS 106
14.3 KITS AND REAGENTS 106
14.3.1 KITS 107
14.3.1.1 PCR KITS 107
14.3.1.2 DNA POLYMERASE KITS 107
14.3.1.3 NUCLEIC ACID ISOLATION KITS 107
14.3.1.4 OTHERS 107
14.3.2 REAGENTS 107
14.3.2.1 FECAL OCCULT BLOOD TEST REAGENTS 108
14.3.2.2 FECAL IMMUNOCHEMICAL TEST REAGENTS 108
14.3.2.3 STOOL DNA TEST REAGENTS 108
14.3.2.4 BLOOD-BASED BIOMARKER TEST REAGENTS 108
14.3.2.5 TISSUE-BASED BIOMARKER TEST REAGENTS 108
14.3.2.6 OTHERS 108
14.3.3 OTHER CONSUMABLES 109
15 ASIA-PACIFIC COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER STAGES 110
15.1 OVERVIEW 111
15.2 STAGE III 114
15.3 STAGE IV 114
15.4 STAGE II 114
15.5 STAGE I 115
15.6 STAGE 0 115
16 ASIA-PACIFIC COLORECTAL CANCER DIAGNOSTICS MARKET, BY AGE GROUP 116
16.1 OVERVIEW 117
16.2 GERIATRIC 120
16.3 ADULTS 120
16.4 PEDIATRIC 121
17 ASIA-PACIFIC COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER TYPE 122
17.1 OVERVIEW 123
17.2 ADENOCARCINOMA 126
17.3 COLORECTAL LYMPHOMA 126
17.4 GASTROINTESTINAL STROMAL TUMORS 126
17.5 CARCINOID TUMORS 127
17.6 LEIOMYOSARCOMAS 127
17.7 MELANOMAS 128
17.8 OTHERS 128
18 ASIA-PACIFIC COLORECTAL CANCER DIAGNOSTICS MARKET, BY END USER 129
18.1 OVERVIEW 130
18.2 HOSPITALS 133
18.3 DIAGNOSTIC CENTERS 133
18.4 CANCER RESEARCH CENTERS 133
18.5 AMBULATORY SURGICAL CENTERS 134
18.6 ACADEMIC INSTITUTES 134
18.7 OTHERS 135

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.